Assess whether a CMC change is a comparability or a new product (83589c)

Situation

In a mid-size sponsor after a complete response letter, scientific-advice briefing book is the evidence after an FAERS cluster in a demographic the trials under-enrolled. Pharmacovigilance medical reviewer has to pick A CMC change is a comparability or A new product for this Pharma & Life Sciences CMC and Development Pathways close using scientific-advice briefing book.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose A CMC change is a comparability / A new product using scientific-advice briefing book after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• Scientific-advice briefing book reads as A CMC change is a comparability once an FAERS cluster in a demographic the trials under-enrolled is lined up to the same Pharma & Life Sciences population.
• Scientific-advice briefing book is closer to A new product after an FAERS cluster in a demographic the trials under-enrolled; A CMC change is a comparability would over-claim this CMC and Development Pathways extract.
• A dual reading is still live in scientific-advice briefing book for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.
• Scientific-advice briefing book is missing the fact pharmacovigilance medical reviewer needs after an FAERS cluster in a demographic the trials under-enrolled; stop this Pharma & Life Sciences close.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether scientific-advice briefing book supports the labeled claim pharmacovigilance medical reviewer would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move a CMC change is for pharmacovigilance medical reviewer.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.